Immunoglobulins in Norway - organization and challenges Brre Fevang - - PowerPoint PPT Presentation

▶

Nov 13, 2022 154 likes •198 views

Regional Health Authorities Northern Western Population 250 Population 1,1 mill 18 employees 25 employees Central South-Eastern Population 740 Population 2,9 mill 14 employees 78 employees Immunoglobulins in

SLIDE 1

Immunoglobulins in Norway

organization and challenges

Børre Fevang Section of Clinical Immunology and Infectious Diseases

Northern

Population 250’ 18’ employees

Central

Population 740’ 14’ employees

Western

Population 1,1 mill 25’ employees

South-Eastern

Population 2,9 mill 78’ employees

Regional Health Authorities

SLIDE 2

Current supply of immunglobulins

Hospital use
All intravenous immunoglobulins
National procurement with long-term contracts with

wholesaler, currently Panzyga

Stockpile of critical medication required
Stable supply
Use at home
All subcutaneous immunoglobulins
No national procurement
No stockpile required
Intermittent shortage of several subcutanous brands

SLIDE 3

Challenges

General increase in the use of immunoglobulins in Norway
Increasing use of subcutanous products as immunmodulating therapy – switch

from IVIG to SCIG

Shortage of alternative intravenous products (Kiovig and Privigen) if severe

side effect of Panzyga

100 000 200 000 300 000 400 000 500 000 600 000 700 000 800 000 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 EST-2018 Gram IVIG SCIG